Foresite Capital Management V, LLC

Foresite Capital Management V, LLC is an investment management entity within the Foresite Capital platform, a specialist healthcare and life sciences franchise headquartered in San Francisco, California. Foresite Capital, founded by Jim Tananbaum, focuses on financing companies across the healthcare ecosystem, spanning therapeutics, genomics, diagnostics, tools, and digitally enabled health services. Foresite Capital Management V, LLC is associated with one of the firm’s later flagship funds, concentrating primarily on growth and crossover opportunities in the life sciences space. The firm operates as an SEC-registered investment advisor and files quarterly Form 13F reports under CIK #0001792206, disclosing its long positions in U.S.-listed securities. These positions are typically a blend of public holdings acquired as part of Foresite’s crossover strategy and follow-on investments in companies the platform has previously backed in private rounds. Because Foresite is fundamentally a life sciences specialist rather than a diversified multi-asset manager, the 13F filings present a focused view into a particular slice of the healthcare innovation universe. On the platform, the 13F History can be used to study how this vehicle’s disclosed holdings have evolved alongside scientific and regulatory cycles in biotech and healthcare technology.

Foresite Capital Management V, LLC pursues a growth-oriented, sector-specialist strategy centered on healthcare and life sciences. The investment approach combines rigorous scientific diligence with fundamental business analysis, leveraging a team of clinicians, scientists, and investment professionals to identify companies at the intersection of transformational biology and scalable business models. The strategy is explicitly "crossover" in nature: the manager backs companies in late private stages and continues to own them through and beyond their IPOs, while also initiating positions directly in public companies where it sees mispriced innovation. The 13F Portfolio Composition therefore tends to include a mix of recently listed former private portfolio companies, established mid- and large-cap biopharma names, genomics and sequencing platforms, healthcare services, and digital health businesses. Holdings are typically concentrated in life sciences sub-sectors tied to secular themes such as precision medicine, gene and cell therapy, data-driven drug discovery, and enabling tools. Turnover in core names is moderate; positions are commonly held through key clinical and regulatory milestones, with adjustments driven by changes in probability of technical success, competitive dynamics, or capital needs. While the broader Foresite platform may employ structured transactions and private rounds, the 13F book itself reflects long-only, U.S.-listed equity exposure. Using the Portfolio Simulator and Backtesting Service, allocators can construct a Simulated Growth Chart based on these disclosed holdings to examine how this crossover biotech exposure would have influenced a notional capital path across different market environments.

Foresite Capital Management V, LLC provides a concentrated window into institutional conviction around cutting-edge healthcare and life sciences innovation. The 13F history shows persistent specialization in therapeutics, tools, and health technology, with a pattern of holding companies through crucial clinical and commercial milestones. This combination of scientific depth and crossover execution produces a portfolio whose capital trajectory is driven more by binary scientific events and regulatory outcomes than by broad macroeconomic forces. On the analytics side, allocators can reconstruct a 13F-based Historical Track Record, normalized to a user-defined notional, to evaluate compounding behavior through biotech bull and bear phases. Examining the strategy’s Sharpe Ratio over various horizons helps quantify whether the elevated volatility and drawdown profile have historically been compensated by superior risk-adjusted outcomes relative to relevant healthcare benchmarks. Overlaying 13F Portfolio Composition data with sector and subsector tags allows for detailed Sector Allocation History analysis, highlighting shifts between therapeutics, tools, and digital health as opportunity sets evolve. Ultimately, the key diagnostic question for an allocator reviewing Foresite Capital Management V, LLC via Performance Backtests Online is whether the manager’s specialized scientific edge and crossover approach continue to justify exposure to the inherent cyclicality and event risk of life sciences—particularly in future regimes where capital costs, regulatory scrutiny, and innovation pathways may differ markedly from the environment in which the existing track record was built.

The risk profile of Foresite Capital Management V, LLC is intrinsically tied to the volatility and binary event risk of the biotechnology and healthcare innovation sectors. Many portfolio companies face catalysts such as clinical readouts, regulatory decisions, reimbursement shifts, or commercialization inflection points, any of which can trigger substantial price moves in either direction. As a result, the portfolio’s Volatility Profile is generally higher than that of broad U.S. equity benchmarks, and more aligned with specialized biotech indices. Single-name drawdowns can be severe when clinical trials fail or competitive landscapes change. Conversely, successful data readouts or regulatory approvals can generate outsized upside in individual positions, producing a lumpy capital trajectory that is characteristic of high-beta life sciences strategies. From a portfolio-construction standpoint, risk is managed via diversification across therapeutic areas, development stages, and business models within healthcare, rather than through broad sector diversification. Hedging, if used, would not be visible within the long-only 13F data, so analysis of Max Drawdown Depth on a 13F-replicated portfolio should be interpreted as the unhedged long-book experience. Historically, such a book can be particularly sensitive to factor rotations away from high-growth and toward defensives, as well as to changes in interest-rate expectations that affect long-duration assets like early-stage biotech.